• Citer

INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes.

par Dunger, David B;Bruggraber, SFA;Mander, AP;Marcovecchio, ML;Tree, T;Chmura, PJ;Knip, M;Schulte, AM;Mathieu, C;Cnop, Miriam ;And other members of, INNODIA consortium
Référence Trials, 23, 1, page (414)
Publication Publié, 2022-05-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes.
Auteur:	Dunger, David B; Bruggraber, SFA; Mander, AP; Marcovecchio, ML; Tree, T; Chmura, PJ; Knip, M; Schulte, AM; Mathieu, C; Cnop, Miriam; And other members of, INNODIA consortium
Informations sur la publication:	Trials, 23, 1, page (414)
Statut de publication:	Publié, 2022-05-01
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	Beta-cell function
	C-peptide
	Master protocol
	Phase 2
	Prevention
	Trials
	Type 1 diabetes
MeSH keywords:	Adolescent
	Adult
	Biomarkers
	COVID-19
	Child
	Diabetes Mellitus, Type 1 -- diagnosis -- drug therapy
	Humans
	SARS-CoV-2
	Treatment Outcome
Langue:	Anglais
Identificateurs:	urn:issn:1745-6215
	info:doi/10.1186/s13063-022-06259-z
	info:pii/10.1186/s13063-022-06259-z
	info:pmid/35585600
	PMC9116021